Table 3.
Proportion of claims and medication annual Medicare reimbursement per physician and changes on claims and Medicare Reimbursement among those receiving industry payments adjusted for physician gender, practice group size, years since graduation from medical school and U.S. region
| Drug name | Per-physician proportion of Claims, % Mean (SD) | Per-physician proportion of annual Medicare spending, % Mean (SD) | Increase in % claims when receiving consulting / compensation payments | Increase in % claims when receiving food / beverage payments# | Increase in % of annual Medicare spending when receiving consulting / compensation payments | Increase in % of annual Medicare spending when receiving food / beverage payments# |
|---|---|---|---|---|---|---|
| rACTH | 0.04 (0.3) | 1.1 (7.4) | 1.57# | 1.64 | 1.87# | 23.13 |
| Adalimumab | 4.0 (4.7) | 25.2 (21.3) | 1.19# | 1.80 | 1.19& | 3.69 |
| Etanercept | 5.3 (5.7) | 31.5 (23.7) | 1.17& | 1.54 | 1.11 | 2.53 |
| Infliximab | 2.3 (5.3) | 9.1 (17.6) | 1.20& | 4.48 | 1.20 | 13.74 |
| Golimumab | 0.3 (1.1) | 1.7 (5.1) | 1.20# | 1.93 | 1.09 | 5.32 |
| Rituximab | 0.4 (1.5) | 1.2 (4.6) | 1.25# | 3.29 | 1.21& | 9.08 |
| Certolizumab | 0.5 (1.9) | 2.0 (6.2) | 1.30# | 2.40 | 1.29# | 6.69 |
| Abatacept | 1.4 (3.0) | 4.8 (9.1) | 1.27# | 2.49 | 1.13 | 6.03 |
| Teriparatide | 0.8 (2.6) | 2.6 (7.5) | 2.13# | 2.29 | 2.10# | 4.45 |
| Denosumab | 1.4 (3.5) | 2.1 (5.9) | 1.22 | 2.94 | 1.19 | 4.04 |
| HCQ | 21.8 (11.2) | 8.0 (14.0) | -- | -- | -- | -- |
| Methotrexate | 29.6 (10.5) | 8.6 (12.9) | -- | -- | -- | -- |
| Prednisone | 32.4 (13.4) | 2.5 (9.5) | -- | -- | -- | -- |
rACTH, Repository corticotropin; HCQ, hydroxychloroquine
#
p<0.0001
&
p<0.05